Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Inoue, Kana ^a   Maeda, Norikazu ^a   Kashine, Susumu ^a   Fujishima, Yuya ^a   Kozawa, Junji ^a   Hiuge Shimizu, Aki ^a   Okita, Kohei ^a   Imagawa, Akihisa ^a   Funahashi, Tohru ^a   Shimomura, Iichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Eating behavior; Glucagon like peptide 1; Liraglutide; Obesity

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; LIRAGLUTIDE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; APPETITE; ARTICLE; BODY MASS; CARDIOVASCULAR SYSTEM; CLINICAL ARTICLE; DISEASE DURATION; DRUG DOSE INCREASE; DRUG EFFECT; FAT INTAKE; FEEDING BEHAVIOR; FEMALE; FOOD PREFERENCE; GLYCEMIC CONTROL; HUMAN; HUNGER; IMMUNOREACTIVITY; IMPEDANCE; INTRAABDOMINAL FAT; JAPANESE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; QUESTIONNAIRE; WAIST CIRCUMFERENCE; WAIST HIP RATIO; BLOOD; GLUCOSE TOLERANCE TEST; JAPAN; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PILOT STUDY; PSYCHOLOGICAL ASPECT; TIME; TREATMENT OUTCOME;

ADIPOSITY; AGED; APPETITE; BIOLOGICAL MARKERS; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; ELECTRIC IMPEDANCE; FEEDING BEHAVIOR; FEMALE; FOOD PREFERENCES; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INTRA-ABDOMINAL FAT; JAPAN; MALE; MIDDLE AGED; OBESITY; PILOT PROJECTS; QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 82355160875     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-109     Document Type: Article

References (36)

1. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med 2007, 356:213-215. 10.1056/NEJMp068177, 17229948.
2. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009, 301:2129-2140. 10.1001/jama.2009.726, 19470990.
3. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004, 24:29-33. 10.1161/01.ATV.0000099786.99623.EF, 14551151.
4. Chilton R, Wyatt J, Nandish S, Oliveros R, Lujan M. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagon-like peptide-1-based therapies. Am J Med 2011, 124:S35-S53. 10.1016/j.amjmed.2010.11.004, 21194579.
5. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003, 77:1146-55.
6. Tanasescu M, Cho E, Manson JE, Hu FB. Dietary fat and cholesterol and the risk of cardiovascular disease among women with type 2 diabetes. Am J Clin Nutr 2004, 79:999-1005.
7. Thanopoulou AC, Karamanos BG, Angelico FV, Assaad-Khalil SH, Barbato AF, Del Ben MP, Djordjevic PB, Dimitrijevic-Sreckovic VS, Gallotti CA, Katsilambros NL, Migdalis IN, Mrabet MM, Petkova MK, Roussi DP, Tenconi MT. Dietary fat intake as risk factor for the development of diabetes: multinational, multicenter study of the Mediterranean Group for the Study of Diabetes (MGSD). Diabetes Care 2003, 26:302-7. 10.2337/diacare.26.2.302, 12547853.
8. Meyer KA, Kushi LH, Jacobs DR, Folsom AR. Dietary fat and incidence of type 2 diabetes in older Iowa women. Diabetes Care 2001, 24:1528-35. 10.2337/diacare.24.9.1528, 11522694.
9. Devore EE, Stampfer MJ, Breteler MM, Rosner B, Hee Kang J, Okereke O, Hu FB, Grodstein F. Dietary fat intake and cognitive decline in women with type 2 diabetes. Diabetes Care 2009, 32:635-40. 10.2337/dc08-1741, 2660474, 19336640.
10. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002, 45:195-202. 10.1007/s00125-001-0719-z, 11935150.
11. Holst JJ, Orskov C. The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. Diabetes 2004, 53:S197-S204. 10.2337/diabetes.53.suppl_3.S197, 15561911.
12. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009, 94:1843-1852. 10.1210/jc.2008-1296, 2690432, 19336511.
13. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 2011, 152:3103-12. 10.1210/en.2011-0174, 21693680.
14. Ryo M, Maeda K, Onda T, Katashima M, Okumiya A, Nishida M, Yamaguchi T, Funahashi T, Matsuzawa Y, Nakamura T, Shimomura I. A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance. Diabetes Care 2005, 28:451-453. 10.2337/diacare.28.2.451, 15677816.
15. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999, 22:1462-1470. 10.2337/diacare.22.9.1462, 10480510.
16. Bergman RN, Ader M, Huecking K, Van Citters G. Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 2002, 51:S212-S220. 10.2337/diabetes.51.2007.S212, 11815482.
17. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR, . Lead-2 Study Group Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009, 32:84-90. 10.2337/dc08-1355, 2606836, 18931095, Lead-2 Study Group.
18. Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, Düring M, Zdravkovic M, Strauss BJ, Garber AJ, . LEAD-2 and LEAD-3 Study Groups Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009, 11:1163-72. 10.1111/j.1463-1326.2009.01158.x, 19930006, LEAD-2 and LEAD-3 Study Groups.
19. Hansotia T, Maida A, Flock G, Yamada Y, Tsukiyama K, Seino Y, Drucker DJ. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 2007, 117:143-152. 10.1172/JCI25483, 1705821, 17187081.
20. Kim Chung le T, Hosaka T, Yoshida M, Harada N, Sakaue H, Sakai T, Nakaya Y. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun 2009, 390:613-618. 10.1016/j.bbrc.2009.10.015, 19850014.
21. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24:275-286.
22. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008, 81:161-168. 10.1016/j.diabres.2008.03.018, 18495285.
23. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007, 56:8-15. 10.2337/db06-0565, 17192459.
24. Raun K, von Voss P, Knudsen LB. Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity (Silver Spring) 2007, 15:1710-1716.
25. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998, 101:515-520. 10.1172/JCI990, 508592, 9449682.
26. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999, 22:1137-1143. 10.2337/diacare.22.7.1137, 10388979.
27. Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J, Beglinger C. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999, 276:R1541-1544.
28. Verdich C, Flint A, Gutzwiller JP, Näslund E, Beglinger C, Hellström PM, Long SJ, Morgan LM, Holst JJ, Astrup A. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001, 86:4382-4389. 10.1210/jc.86.9.4382, 11549680.
29. Kawate R, Yamakido M, Nishimoto Y, Bennett PH, Hamman RF, Knowler WC. Diabetes mellitus and its vascular complications in Japanese migrants on the Island of Hawaii. Diabetes Care 1979, 2:161-70. 10.2337/diacare.2.2.161, 520120.
30. Marshall JA, Hamman RF, Baxter J. High-fat, low-carbohydrate diet and the etiology of non-insulin-dependent diabetes mellitus: the San Luis Valley Diabetes Study. Am J Epidemiol 1991, 134:590-603.
31. Tsunehara CH, Leonetti DL, Fujimoto WY. Diet of second-generation Japanese-American men with and without non-insulin-dependent diabetes. Am J Clin Nutr 1990, 52:731-8.
32. Tinker LF, Bonds DE, Margolis KL, Manson JE, Howard BV, Larson J, Perri MG, Beresford SA, Robinson JG, Rodríguez B, Safford MM, Wenger NK, Stevens VJ, Parker LM. Women's Health Initiative. Low-fat dietary pattern and risk of treated diabetes mellitus in postmenopausal women: the Women's Health Initiative randomized controlled dietary modification trial. Arch Intern Med 2008, 168:1500-11. 10.1001/archinte.168.14.1500, 18663162.
33. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287:E1209-E1215. 10.1152/ajpendo.00237.2004, 15353407.
34. Ansar S, Koska J, Reaven PD. Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovasc Diabetol 2011, 10:61. 10.1186/1475-2840-10-61, 3184260, 21736746.
35. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010, 59:1030-1037. 10.2337/db09-1694, 2844811, 20068138.
36. Gaspari T, Liu H, Welungoda I, Hu Y, Widdop RE, Knudsen LB, Simpson RW, Dear AE. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model. Diab Vasc Dis Res 2011, 8:117-124. 10.1177/1479164111404257, 21562063.